Related Experiment Video
Updated: Nov 21, 2025

09:57
How to Measure Cortical Folding from MR Images: a Step-by-Step Tutorial to Compute Local Gyrification Index
Published on: January 2, 2012
28.3K
Cortical thickness in Parkinson's disease: a coordinate-based meta-analysis
LiQin Sheng1, PanWen Zhao2, HaiRong Ma1
1Department of Neurology, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, PR China.
Aging
|January 18, 2021
Summary
This study found no consistent cortical thickness changes in Parkinson's disease (PD) patients, suggesting cortical thickness is an unreliable neuroimaging marker for PD diagnosis. Further research needs to address population and imaging heterogeneity.
Area of Science:
- Neuroimaging
- Neurodegenerative Diseases
- Brain Anatomy
Background:
- Parkinson's disease (PD) is a common neurodegenerative disorder impacting the cerebral cortex.
- Cortical thickness (CTh) analysis using surface-based morphometry (SBM) is frequently used to detect gray matter changes in PD.
- Existing CTh findings in PD lack consistency and require systematic review.
Purpose of the Study:
- To conduct a comprehensive coordinate-based meta-analysis (CBMA) of cortical thickness alterations in Parkinson's disease.
- To systematically evaluate the reliability of CTh as a neuroimaging marker for PD.
Main Methods:
- A coordinate-based meta-analysis (CBMA) was performed on 38 CTh studies.
- Data included 1,843 patients with PD and 1,172 healthy controls.
- The latest seed-based d mapping software was utilized.
Main Results:
- No significantly consistent cortical thickness alterations were identified in patients with PD compared to controls.
- This suggests that CTh is not a reliable neuroimaging marker for PD.
Conclusions:
- The inconsistency in CTh findings may stem from clinical population heterogeneity, diverse imaging methods, and small sample sizes.
- Future PD neuroimaging studies should control for confounding factors to ensure robust and reproducible results.
Related Concept Videos
Parkinson's Disease: Overview
1.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
Parkinson's Disease: Treatment
758
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
758
Neural Regulation
41.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
41.9K

